00:00

Now what are the marijuana companies halted today was Ontario based Metro Health CEO Michael Haynes that joins us for a look at what drove the surge and some of the mania today. And we'll we'll talk about the overall outlook for the cannabis business and his company as well. Michael Hanes is right here. Hello sir. Thanks for having me. So getting gray hairs today or what do you think. What do you think of that. Well it was. Listen it's an exciting time for any four for an industry where you have what what it was transpiring in ours. We had a couple of years. The creation of new regulations that put into effect an industry that will grow to 5 billion dollars in revenue in a very short period of time. We're only about 20 percent of the way into that industry. It's growing a lot faster than anybody expected than was forecast. So as I said we're about 20 percent of the way into a billion dollar industry that will mature within the next two to three years. And right on the heels of that we have a five to 10 billion dollar industry conservatively estimated recreational market that's going to come in. So you know if if I think the reality and the focus of recreational cannabis is becoming a lot crisper a lot more real. And. And now markets are starting to take notice of it . Any CEO likes to see a stock go up. And we'll talk about other things seriously. But today was so wild. Do you do you Are you concerned at all that your stock price and your valuation getting ahead of your actual assets. Well I think that if you if you if you look at the capacity of our company our goal from the outset was to get to 15 percent market share and to maintain it. And that was at about a 12000 kilo production capacity . Well we're going to be at that capacity by the end of this year a lot sooner than we expected. And the market's maturing a lot faster than expected. So the you know I'm not going to opine on on on on on on the rise of the stocks but the support in terms of of the operating fundamentals of these companies is is there. These companies are growing into into into a market that's maturing much faster than anybody expected. Let's talk about your earnings so some very impressive numbers revenue up 180 percent year over year Grams sold up 127 the number of patients that you signed on up to 53 percent. However according to GMP you missed on revenue a little bit. Their expectations you missed on adjusted EBITDA Were there some headwinds in the quarter. The main had when we came off of a very very strong first quarter. So we didn't have as much product in the inventory as as we could have used to grow the business to its fullest potential in that quarter . That's caught up. Definitely caught up in Q3. You'll feel it strongly in Q4 as well. And as I said we are where we're operating now at full capacity and also we're building out our capacity as we're speaking and we're kind of ahead of the game . Now in terms of the amount of product that we're going to need to grow it our target which is at around 10 percent growth per month we're currently sitting at about 15 percent market share and we've built our business too. And we and we and we allocate our CapEx based on being able to maintain that 15 percent market share on a go forward basis in the medical market and into the recreational market when it comes and when there's opportunities around for us to grow beyond that we'll take advantage of you struck a deal today you're buying Apollo applied research for cash and stock is at roughly 4 million. Is that about right . Roughly in that range how about that. Okay so and then they have two very interesting big studies going on right now one with PTSD I guess the only have two studies for for chronic pain . They have other studies underway that are that are to be announced and they're very strategic for us. You know we we we are objective and I think we're achieving it is to be the most physician centric license producer out there so we really talk to the physician they're really out of our front line in terms of the consumer who we're talking to and and Apollo adds a really important research component to that dialogue that we have with physicians. We've seen some of your rivals Africa organic gram and some other ones raising cash. Have you done that lately at all and are you're looking for acquisition more acquisitions. We we we haven't done we haven't on a raise in this last round of of raises that have been going on where we're adequately capitalized we have a very strong balance sheet . We're not participating in that round. Okay fair enough. The one I was thinking of was I will come back to me. Doesn't matter. Okay so what about competition you you talk about the growth there's such interest there's a demand regulatory environment is getting better. Can you maintain that 15 percent or do you see other bigger players moving into the space. I think we can maintain it. And that's that's our plan. That's how we allocate our CapEx. That's how that's how we run the strategy within our company. You know the interest in our space as well is is expanding exponentially and you know a lot of what we saw today is you know we're seeing now the meat market is not just fringe people who are interested in cannabis. It's now getting more broad based and I think a lot of what was driving the market today in the capital has come in the market and we'll see it in the future it's coming more globally as what we're starting to see .